Post by
stockfy on Nov 22, 2017 4:02am
Case study: ZOM's uplisting (NYSE) and SNYR
Zomedica Pharmaceuticals (ZOM) is the perfect case study that shows how its uplisting to NYSE boosts market awareness bringing ZOM's valuation in line with peers. I wish I had bought more ZOM shares before the uplisting. See ZOM's recent performance.
This example demonstrates how Synergy CHC (SNYR) will benefit from the uplisting.
With $7 million adjusted EBITDA in 2017 (despite that most of its brands didn't sell for the full year), SNYR is grossly undervalued compared to the peers on NYSE and Nasdaq.
I expect SNYR will make at least $8 million adjusted EBITDA in 2018.
SNYR has high insider ownership (55%) while billion-dollar company Knight (GUD) owns another 20%, so insiders interests are fully aligned with shareholders':
https://seekingalpha.com/pr/17009183-synergy-chc-corp-announces-third-quarter-2017-results